How big is Black Diamond Therapeutics, Inc.?

As of Jun 18, Black Diamond Therapeutics, Inc. has a market capitalization of 131.92 million and reported net sales of 70.00 million with a net profit of 5.09 million over the latest four quarters. Shareholder's funds are 83.28 million, and total assets are 122.64 million.

Market Cap: As of Jun 18, Black Diamond Therapeutics, Inc. has a market capitalization of 131.92 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 70.00 million and a net profit of 5.09 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 83.28 million, while total assets were reported at 122.64 million.

What does Black Diamond Therapeutics, Inc. do?

Black Diamond Therapeutics, Inc. is a precision oncology medicine company with a market cap of $131.92 million, reporting net sales of $70 million and a net profit of $57 million as of March 2025. Key metrics include a P/E ratio of 29.00 and a return on equity of 3.60%.

Overview: <BR>Black Diamond Therapeutics, Inc. is a precision oncology medicine company operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>- Most recent Net Sales: 70 Million (Quarterly Results - Mar 2025) <BR>- Most recent Net Profit: 57 Million (Quarterly Results - Mar 2025) <BR>- Market-cap: USD 131.92 Million (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 29.00 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -1.05 <BR>- Return on Equity: 3.60% <BR>- Price to Book: 0.93 <BR><BR>Contact Details: <BR>- Address: ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA : 02142 <BR>- Tel: 1 617 4175868 <BR>- Website: https://www.blackdiamondtherapeutics.com/

Should I buy, sell or hold Black Diamond Therapeutics, Inc.?

Who are in the management team of Black Diamond Therapeutics, Inc.?

As of March 2022, the management team of Black Diamond Therapeutics, Inc. includes Mr. Robert Ingram (Independent Chairman), Dr. David Epstein (CEO), and several directors: Dr. Bradley Bolzon, Dr. Kapil Dhingra, Mr. Alexander Mayweg, Dr. Ali Behbahani, and Dr. Samarth Kulkarni. The team features a mix of independent directors and executives, ensuring diverse leadership.

As of March 2022, the management team of Black Diamond Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Robert Ingram, Independent Chairman of the Board<BR>- Dr. David Epstein, President, Chief Executive Officer, and Director<BR>- Dr. Bradley Bolzon, Director<BR>- Dr. Kapil Dhingra, Director<BR>- Mr. Alexander Mayweg, Director<BR>- Dr. Ali Behbahani, Independent Director<BR>- Dr. Samarth Kulkarni, Independent Director<BR><BR>This team comprises a mix of independent directors and executives, reflecting a diverse leadership structure within the company.

Is Black Diamond Therapeutics, Inc. technically bullish or bearish?

As of September 4, 2025, Black Diamond Therapeutics, Inc. shows a bullish trend with strong indicators, despite some caution from weekly and monthly KST readings, and has a year-to-date return of 56.54%, outperforming the S&P 500's 12.22% return.

As of 4 September 2025, the technical trend for Black Diamond Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The monthly RSI indicates a bullish stance, and the daily moving averages are also bullish. However, the weekly KST is mildly bearish, and the monthly KST is bearish, which introduces some caution. The Bollinger Bands show a bullish signal on the weekly but are mildly bearish on the monthly. The overall stance is bullish, supported by strong OBV readings on both weekly and monthly timeframes.<BR><BR>In terms of performance, the stock has a year-to-date return of 56.54%, significantly outperforming the S&P 500's 12.22% return, although it has underperformed over the 1-year, 3-year, and 5-year periods compared to the benchmark.

Is Black Diamond Therapeutics, Inc. overvalued or undervalued?

As of October 17, 2025, Black Diamond Therapeutics, Inc. is considered attractive but overvalued with a P/E ratio of 29 compared to the sector average of 12.03, despite a strong year-to-date return of 87.38% that contrasts with its negative long-term performance.

As of 17 October 2025, the valuation grade for Black Diamond Therapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, given its P/E ratio of 29, which is significantly higher than the peer average of approximately 12.03 for companies in the same sector. Additionally, the EV to EBITDA ratio stands at 0.54, while the PEG ratio is notably low at 0.27, suggesting that the stock may not be justified at its current price level.<BR><BR>In comparison to its peers, Black Diamond Therapeutics, Inc. has a higher valuation than Harpoon Therapeutics, Inc., which has a P/E of -28.51, and Selecta Biosciences, Inc., with a P/E of -6.42, both of which are considered risky investments. The company's recent stock performance shows a year-to-date return of 87.38%, significantly outperforming the S&P 500's return of 13.30% in the same period, but this strong performance contrasts with its long-term returns, which have been negative over the past five years.